Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)

EARLY_PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 27, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Type 1 Primary Hyperoxaluria

Interventions

DRUG

YOLT-203

The IP is administered intravenously at the predetermined dose.

Trial Locations (1)

Guangzhou Women and Children's Medical Center, Guangzhou

All Listed Sponsors

lead

Guangzhou Women and Children's Medical Center

OTHER